Amantadine is not a controlled substance. It is not listed on any of the five schedules of the Controlled Substances Act, and the DEA does not classify it as a drug with significant abuse or dependency potential. It is, however, a prescription medication, meaning you cannot buy it over the counter and need a doctor’s order to obtain it.
Why Amantadine Isn’t Scheduled
The DEA places drugs on controlled substance schedules based on their potential for abuse, whether they have accepted medical use, and how likely they are to cause physical or psychological dependence. Amantadine doesn’t meet these criteria. Clinical research has shown it combines dopamine-related and glutamate-related effects with a long history of safe clinical use, and it has not demonstrated the reinforcing properties that characterize drugs of abuse.
This means your pharmacy can fill an amantadine prescription without the restrictions that apply to controlled substances. There’s no limit on refills tied to scheduling, no requirement for a new written prescription each month, and no special DEA registration needed for prescribers beyond their standard medical license.
What Amantadine Is Used For
Amantadine was originally developed as an antiviral drug for influenza A, though it’s rarely used for that purpose today. Its primary role now is in treating Parkinson’s disease, where it helps with both the core symptoms of stiffness and tremor and the involuntary movements (dyskinesias) that can develop as a side effect of long-term Parkinson’s medication. It works through an unusual combination of boosting dopamine activity and blocking a type of brain receptor involved in excessive nerve signaling.
Doctors also prescribe amantadine to manage movement side effects caused by certain psychiatric medications. In some cases, it’s used off-label for fatigue related to multiple sclerosis or to aid recovery after traumatic brain injury.
How It’s Prescribed
The standard dose for Parkinson’s disease is 100 mg twice daily when used on its own, though some patients start at 100 mg once daily and increase gradually over one to several weeks. In cases where 200 mg per day isn’t enough, doctors may raise the dose to as high as 400 mg daily in divided doses. An extended-release capsule formulation is also available, taken once daily at bedtime.
People with reduced kidney function need lower doses because the body clears amantadine almost entirely through the kidneys. For older adults (65 and over), a lower daily dose of 100 mg is typical regardless of the condition being treated.
Side Effects Worth Knowing About
Amantadine’s side effects are one reason it requires a prescription even though it’s not a controlled substance. The most distinctive is livedo reticularis, a mottled reddish-blue, net-like pattern that appears on the skin, most often on the legs. This shows up in 20 to 40 percent of patients taking amantadine for Parkinson’s disease. It’s generally harmless and fades after stopping the drug, though in rare cases it can worsen over time and lead to leg ulcers.
Other common side effects include dizziness, insomnia, nausea, and swelling in the ankles or feet. At higher doses or in older patients, amantadine can cause hallucinations, confusion, or difficulty concentrating. These neurological effects are more likely in people with kidney problems, since impaired kidneys allow the drug to build up to higher levels in the body.
Stopping amantadine abruptly after long-term use can occasionally trigger a rebound worsening of Parkinson’s symptoms, so doctors generally recommend tapering the dose gradually rather than quitting all at once. This isn’t the same as physical dependence in the way controlled substances cause it. Instead, it reflects the brain readjusting to the loss of the drug’s dopamine-boosting effects.
How It Compares to Controlled Parkinson’s Drugs
Some medications used alongside Parkinson’s treatments do carry controlled substance restrictions. Certain sleep aids or anti-anxiety drugs prescribed to manage Parkinson’s-related symptoms fall under Schedule IV, for example. Amantadine is distinct from these because it doesn’t produce euphoria, doesn’t reinforce drug-seeking behavior, and hasn’t shown potential for recreational misuse in clinical studies. Research specifically examining whether amantadine might amplify the rewarding effects of other substances found that it did not enhance the subjective or reinforcing effects of stimulants.
This profile makes amantadine straightforward to prescribe and refill compared to controlled medications, which is a practical advantage for patients managing a chronic condition like Parkinson’s disease.